The three-year signature initiative is designed to make learning about health and disease engaging, accessible, and exciting for students in grades 6-8, primarily in under-resourced schools across the country.
The programme will kick off with a Virtual Field Trip to AstraZeneca's Gaithersburg, MD, research laboratories, which will premiere on Tuesday, October 8, 2019 at 1:00 p.m. ET / 10:00 a.m. PT.
The programme, Generation Health: How Science Powers Us, will provide students first-hand access to the technology and scientists working to create medical breakthroughs for the world's most pressing health problems. Educators, parents and students are invited to register here.
Participants are encouraged to join a live Twitter chat during the premiere by submitting questions and sending pictures using #GenerationHealthVFT.
Generation Health: How Science Powers Us will provide hands-on, standards-aligned STEM learning activities where students investigate both preventative measures and innovative solutions to key health concerns in the areas of oncology, cardiovascular, and respiratory disease.
The programme will also offer resources for employee engagement in the classroom.
As part of this program, Generation Health provides a suite of educational resources, including, Learning Undefeated's Drop Anywhere Labs, custom-outfitted STEM learning spaces built from modified shipping containers.
These light, easy-to-access and inexpensive labs provide a range of career and skills education for middle school students, as well as flexible in-classroom resources that empower teachers and enables them to serve up to four classes simultaneously.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886